Which statement best describes the pathophysiology of retinal vein occlusion and its initial management?

Which statement best describes the pathophysiology of retinal vein occlusion and its initial management?

• A. Arteries become hardened due to high blood pressure or cholesterol, compressing a retinal vein, causing pooling and macular edema; treatment includes AntiVEGF injections and systemic management by the primary care physician.
• B. It is caused by a blockage in the optic nerve; treated with corticosteroids.
• C. It results from increased intraocular pressure alone; treated with glaucoma medications.
• D. It is due to a retinal tear; treated with laser barrier laser.

Answer: (A)

Retinal vein occlusion happens when a sclerotic retinal artery at an arteriovenous crossing compresses the adjacent vein, leading to impaired venous outflow, venous congestion, hemorrhages, and leakage that causes macular edema. This vascular mechanism explains the initial treatment approach: focus on reducing the macular edema and preventing further vascular complications. The cornerstone therapy is intravitreal anti-VEGF injections, which decrease vascular permeability and edema, helping to improve or stabilize vision. At the same time, addressing systemic risk factors is essential, so management by the primary care physician to control blood pressure, cholesterol, and blood sugar is important to reduce ongoing vascular risk. Ocular imaging such as OCT helps quantify the edema and guide treatment, and fluorescein angiography assesses retinal perfusion and ischemia, which can influence long-term decisions like laser therapy if neovascularization or extensive ischemia develops. The other statements describe problems that are not the mechanism of retinal vein occlusion and are not the initial management approach.

Retinal vein occlusion happens when a sclerotic retinal artery at an arteriovenous crossing compresses the adjacent vein, leading to impaired venous outflow, venous congestion, hemorrhages, and leakage that causes macular edema. This vascular mechanism explains the initial treatment approach: focus on reducing the macular edema and preventing further vascular complications. The cornerstone therapy is intravitreal anti-VEGF injections, which decrease vascular permeability and edema, helping to improve or stabilize vision. At the same time, addressing systemic risk factors is essential, so management by the primary care physician to control blood pressure, cholesterol, and blood sugar is important to reduce ongoing vascular risk. Ocular imaging such as OCT helps quantify the edema and guide treatment, and fluorescein angiography assesses retinal perfusion and ischemia, which can influence long-term decisions like laser therapy if neovascularization or extensive ischemia develops. The other statements describe problems that are not the mechanism of retinal vein occlusion and are not the initial management approach.